Biotech Leadership in a Dynamic Oncology Environment

In 2023, the global pharmaceutical prescription drug market was $1.1 trillion. Oncology accounted for roughly 25% of that market and makes up roughly half of the clinical research pipeline. Despite advancements in oncology drug approvals, chemotherapy remains standard of care among many tumors with high incidence and unmet medical need. While chemotherapy may kill cancer cells, it also results in indiscriminate damage to healthy tissues. Antibody-drug conjugates (ADCs), or "smart chemo", have the potential to deliver potent cytotoxic agents to tumor cells while avoiding collateral damage to normal cells. The ADC space is powered by technological innovation in order to strike the right balance between efficacy and toxicity. ADC Therapeutics is a pioneer in the space, as the only public biotech company with an approved ADC, a clinical pipeline, and a research platform that enables advancement of next-generation ADCs. As companies seek to have impact in this evolving landscape, leadership and culture play a key role in their ultimate success. Hear the perspective of an experienced pharmaceutical and biotech leader on navigating this dynamic oncology environment.

Ameet Mallik is CEO of ADC Therapeutics, a public commercial-stage oncology biotech company, which is a leader and pioneer in the field of antibody-drug conjugates. Before joining ADC Therapeutics in 2022, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company. Mr. Mallik has over 25 years of industry experience and spent more than 16 years at Novartis where he last served as Executive Vice President and Head, U.S. Oncology. Before that, Mr. Mallik served as Global Head, Marketing, Value and Access, and Head, Latin America and Canada for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and held a number of commercial and leadership roles across Novartis and Sandoz during his tenure there. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the boards of directors of ADC Therapeutics, Atara Biotherapeutics, and NJ-based non-profit organization, NJ LEEP. Mr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania as well as an MS in Biotechnology and a BS in Chemical Engineering, both from Northwestern University.